Everhart Financial Group
CTKB icon

Everhart Financial Group’s Cytek Biosciences CTKB Stock Holding History

Everhart Financial Group’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$77.3K Hold
12,962
– – ﹤0.01% 485
2026
Q2 		$57.4K Hold
12,962
– – ﹤0.01% 475
2026
Q1 		$56.6K Hold
12,962
– – ﹤0.01% 456
2025
Q4 		$65.5K Hold
12,962
– – 0.01% 415
2025
Q3 		$45K Hold
12,962
– – ﹤0.01% 388
2025
Q2 		$44.1K Buy
+12,962
New +$43.2K 0.01% 339

Other funds holding CTKB

Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
CenterBook Partners
CenterBook Partners Greenwich, Connecticut $2.18B AUM 12.5% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Bailard
Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return
NorthCrest Asset Manangement
NorthCrest Asset Manangement Plymouth, Minnesota $4.24B AUM 32.82% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

Everhart Financial Group's CTKB Position: Q3 2026 in Review

Everhart Financial Group held its Cytek Biosciences (CTKB) position steady in Q3 2026 at 12,962 shares worth $77.3K. The position accounts for ﹤0.01% of the portfolio, ranked #485.

Everhart Financial Group first reported a position in CTKB in Q2 2025 and has held it in 6 quarters since. 29 funds tracked by Wall St. Rank hold CTKB as of Q3 2026.

  • Everhart Financial Group held 12,962 shares of Cytek Biosciences worth $77.3K as of Q3 2026.
  • Everhart Financial Group left its Cytek Biosciences share count unchanged in Q3 2026.
  • Cytek Biosciences made up ﹤0.01% of Everhart Financial Group's portfolio in Q3 2026, its #485 holding.
  • Everhart Financial Group first reported a position in Cytek Biosciences in Q2 2025 and has held it in 6 quarters since.
  • 29 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2026.

Based on Everhart Financial Group's 13F filing for Q3 2026, filed 8 Oct 2026.